Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

NCT02471144 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

162

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Severe Plaque-type Psoriasis

Interventions

BIOLOGICAL: Experimental : Secukinumab low dose
BIOLOGICAL: Experimental: Secukinumab high dose
BIOLOGICAL: Placebo Comparator: Secukinumab Placebo
BIOLOGICAL: Active Comparator: Etanercept

Sponsor

Novartis Pharmaceuticals